Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage

Phase 2TerminatedNCT05953103

Simcere Pharmaceutical Co., Ltd80 enrolled

Overview

The SIM0355-201 trial is a multicenter, randomized, double-blind, placebo-controlled exploratory clinical trial with the main study objective of evaluating the safety and tolerability of different doses of Edaravone Dexborneol concentrate injection (Sanbexin IV) combined with conventional medical therapy in patients with intracerebral hemorrhage (ICH). The subject had a clinical diagnosis of ICH, within 6-24 hours from stroke onset to start of study treatment, with the bleeding site in basal ganglia and a hematoma volume ≤ 30 ml at the bleeding site. The trial was divided into two periods (Period A and Period B), with Period A being a dose escalation period divided into two dose levels: the first dose level group (Dose 1 group: Sanbexin IV 37.5 mg; placebo group) and the second dose level group (Dose 2 group: Sanbexin IV 62.5 mg; placebo group). Safety was assessed unblinding after the end of study treatment for all subjects in the first dose level group and escalated to the second dose level if the "safe dose" criterion was met, otherwise the trial was terminated; safety was assessed unblinding after the end of study treatment for all subjects in the second dose level group and the 62.5 mg dose level was selected to enter Stage B if the "safe dose" criterion was met, otherwise the 37.5 mg dose level was selected to enter Stage B. Period B is the expansion phase, where the sample size is increased based on the optimal dose selected in Phase A to observe efficacy and safety.

Study Type

INTERVENTIONAL

Allocation

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. the subject himself or her legal representative has signed the informed consent form; 2. aged ≥ 18 years and ≤ 80 years, male or female; 3. clinical diagnosis of cerebral hemorrhage, in line with the Chinese Medical Association Neurology Score issued by the "Key Points in the Diagnosis of Various Major Cerebrovascular Diseases in China 2019" cerebral hemorrhage diagnostic criteria \[1\]; 4. the bleeding center site is located in the basal ganglia; 5. intracranial hematoma volume ≤ 30 ml; 6. NIHSS score at enrollment total score ≥ 6 points and ≤ 20 points, and the sum of items 5 and 6 ≥ 2 points; 7. coma degree is mild to moderate, Glasgow Coma Scale (GCS) ≥ 9 points; 8. the time from the onset of this stroke to the start of study treatment is 6 to 24 hours (subjects who sign the informed consent form should receive study treatment as soon as possible, some subjects meet the criteria during the screening period, more than 24 hours when starting study treatment, this patient should terminate the study treatment); 9. mRS score of 0 or 1 before onset. Exclusion Criteria: 1. allergic to edaravone, dextromethorphan or contained excipients; 2. stroke within the past 3 months; 3. other concomitant sites of hematoma volume \> 5ml, or the need for external ventricular drainage of patients with intraventricular hemorrhage; 4. patients with obstructive hydrocephalus; 5. drugs, vascular structural damage or coagulation disorders caused by cerebral hemorrhage; 6. vital signs unstable, suspected cerebral hernia, deep coma or anisocoria and other critical manifestations; 7. after this onset has been applied edaravone or dextromethorphan components (such as edaravone injection, Angong Niuhuang pills, Xingnaojing, etc.) of drugs, or has applied a total of more than 2 times the daily recommended dose of the instructions of the following drugs: citicoline, oxiracetam, piracetam, ulinastatin; 8. planned surgical evacuation of hematoma, including: craniotomy hematoma evacuation, minimally invasive surgery and decompressive craniectomy; 9. ALT or AST \> 2.0 × ULN or previously known liver disease, such as acute hepatitis, chronic active hepatitis, cirrhosis, etc., previously known kidney disease, renal insufficiency, serum creatinine \> 1.5 × ULN or creatinine clearance \< 50 mL/min; 10. Suffering from other bleeding disorders, such as thrombocytopenic purpura, bleeding tendency caused by vascular injury, hemophilia and other coagulation disorders, gastrointestinal ulcers, urinary tract bleeding, hemoptysis, etc.; 11. Presence of severe, progressive, or uncontrolled symptoms of renal, hepatic, hematological, gastrointestinal, pulmonary, cardiovascular, neurological, or cerebral disease that, in the opinion of the investigator, place the subject at unacceptable risk by participating in this study; 12. With severe active bacterial or viral infection; 13. Concurrent malignancy or ongoing anti-tumor therapy; 14. With severe systemic disease, expected survival \< 90 days; 15. Patients with severe mental disorders and dementia; 16. Patients who are pregnant, lactating and planning pregnancy; 17. Reasons for other investigators' unsuitability to participate in this trial.

Outcomes

Primary Outcomes

Incidence of serious adverse events (SAEs) up to 90 days after the first dose of treatment

Time frame: up to 90 days after the first dose of treatment

Secondary Outcomes

Incidence of deaths up to 90 days after the first dose of treatment

Time frame: up to 90 days after the first dose of treatment

Proportion of subjects with AEs, AEs leading to dose interruption or discontinuation, AEs related to study drug, AEs of special interest (AESls), and with abnormal vital signs, abnormal physical examination findings and abnormal laboratory tests results

Time frame: up to 90 days after the first dose of treatment

Proportion of subjects with modified Rankin Score (mRS) 0-2, which assesses the degree of disability or dependence in daily activities, with scores ranging from 0 (no symptoms) to 6 (death), at 90 days after the first dose of treatment

Time frame: at 90 days after the first dose of treatment

Proportion of subjects with modified Rankin Score (mRS) 0-1, which assesses the degree of disability or dependence in daily activities, with scores ranging from 0 (no symptoms) to 6 (death), at 90 days after the first dose of treatment

Time frame: at 90 days after the first dose of treatment

Distribution of subjects with modified Rankin Score (mRS), which assesses the degree of disability or dependence in daily activities, with scores ranging from 0 (no symptoms) to 6 (death), at 14, 30, 90 days after the first dose of treatment

Time frame: at 14, 30, 90 days after the first dose of treatment

Distribution of subjects with Glasgow Outcome Score (GOS), which measures functional outcome, with scores ranging from I (Dead) to V (Good Recovery), at 14, 30, 90 days after the first dose of treatment

Time frame: at 14, 30, 90 days after the first dose of treatment

Change from baseline in National Institutes of Health Stroke Scale (NIHSS), which quantifies the impairment caused by a stroke, with scores ranging from 0 (no stroke symptoms) to 42 (the most severe stroke)

Time frame: at 14, 30, 90 days after the first dose of treatment

Proportion of subjects with National Institutes of Health Stroke Scale (NIHSS) 0-2, which quantifies the impairment caused by a stroke, with scores ranging from 0 (no stroke symptoms) to 42 (the most severe stroke)

Time frame: at 14, 30, 90 days after the first dose of treatment

Proportion of subjects with Barthel index (BI), which measures a person's ability to complete activities of daily, with scores ranging from 0 (fully dependent) to 20 (fully independent), at 90 days after the first dose of treatment

Time frame: at 90 days after the first dose of treatment

Imaging endpoints：Change from baseline in perihematomal edema volume (PHEv) and hematoma volume (HV) in milliliters

Time frame: at 3, 7, 14 days after the first dose of treatment

Imaging endpoints：Change from baseline in edema extension distance (EED) in millimetres c) Change from baseline in relative perihematomal edema (PHEv/Hv) in odds ratio

Time frame: at 3, 7, 14 days after the first dose of treatment

Imaging endpoints: Change from baseline in relative perihematomal edema (PHEv/Hv) in odds ratio

Time frame: at 3, 7, 14 days after the first dose of treatment

Plasma pharmacokinetic endpoints: Cmax: maximum observed plasma concentration for edaravone and dexborneol

Time frame: 1 hour pre-dose and 1, 2 hour post-dose at 3, 14 days after the first dose of treatment

Plasma pharmacokinetic endpoints: Tmax: time to reach the maximum plasma concentration (Cmax) for edaravone and dexborneol

Time frame: 1 hour pre-dose and 1, 2 hour post-dose at 3, 14 days after the first dose of treatment

Plasma pharmacokinetic endpoints: AUC(0-inf): area under the plasma concentration-time curve from time 0 to infinity for edaravone and dexborneol

Time frame: 1 hour pre-dose and 1, 2 hour post-dose at 3, 14 days after the first dose of treatment

Plasma biomarker endpoints: a) Change from baseline in white blood cell count (WBC) in 109/L; b) Change from baseline in C-reactive protein (CRP), Thioredoxin (TRX) and matrix metalloproteinases (MMP) in mg/L

Time frame: at 3, 7, 14 days after the first dose of treatment

Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes